Literature DB >> 19819282

Increased percentage of B cells in patients with more advanced hepatocellular carcinoma.

Jiunn-Chang Lin1, Yung-Luen Shih, Pei-Ju Chien, Chien-Liang Liu, Jie-Jen Lee, Tsan-Pai Liu, Wen-Ching Ko, Chwen-Ming Shih.   

Abstract

To compare immunologic phenotypes between (1) hepatocellular carcinoma (HCC) patients and a healthy population and (2) more advanced and early stage HCC patients, we studied 45 HCC patients and 46 healthy controls from January 2006 to January 2008. Using fluorescent activated cell sorter (FACS) analysis, HCC patients were demonstrated to exhibit stronger phagocytosis of granulocytes and monocytes and more peripheral blood mononuclear cells (PBMCs) in the G2/M phase compared with healthy volunteers. By contrast, lower percentages of B and T(h) lymphocytes were also found in the peripheral blood of HCC patients than in the healthy population. Most importantly, a higher percentage of B cells was found in patients with advanced HCC than in those with early HCC in terms of TNM stage (II and III vs I, p = 0.004), the Japanese Integrated Scoring system (2-3 vs 0-1, p = 0.0235), and tumor numbers (> or =2 vs 1, p = 0.005). In conclusion, our findings suggested that HCC patients might exhibit enhanced innate immunity and reduced adaptive immunity compared with healthy volunteers. A higher percentage of B cells was found in patients with more advanced HCC compared with patients with early stage HCC, which might serve as an indicator of the severity of HCC.

Entities:  

Mesh:

Year:  2010        PMID: 19819282     DOI: 10.1016/j.humimm.2009.10.003

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  3 in total

1.  Highly differential count of circulating and tumor infiltrating immune cells in patients with non-HCV/non-HBV hepatocellular carcinoma.

Authors:  Markus Bo Schoenberg; Tong Zhu; Jingcheng Hao; Julian Nikolaus Bucher; Xiaokang Li; Xinyu Li; Yongsheng Han; Dionysios Koliogiannis; Michaela Svihla; Markus Otto Guba; Jens Werner; Alexandr V Bazhin
Journal:  Cancer Immunol Immunother       Date:  2021-09-28       Impact factor: 6.630

Review 2.  B cell regulation in cancer and anti-tumor immunity.

Authors:  Anushruti Sarvaria; J Alejandro Madrigal; Aurore Saudemont
Journal:  Cell Mol Immunol       Date:  2017-06-19       Impact factor: 11.530

3.  Decreased of BAFF-R expression and B cells maturation in patients with hepatitis B virus-related hepatocellular carcinoma.

Authors:  Apichaya Khlaiphuengsin; Natthaya Chuaypen; Pimpayao Sodsai; Supranee Buranapraditkun; Tadech Boonpiyathad; Nattiya Hirankarn; Pisit Tangkijvanich
Journal:  World J Gastroenterol       Date:  2020-05-28       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.